INmune Bio, Inc.
XPro1595
Alzheimer's disease
Date
TBD
FDA decision · Date TBD estimated
What's at stake
An FDA complete response letter on XPro1595 for Alzheimer's disease is in focus around Date TBD.
Primary source
· SEC 8-K
verified 13h ago
“With FDA Fast Track designation in hand, End-of-Phase 2 alignment secured, and an additional imaging biomarker result that further reinforces our patient selection strategy, we have systematically addressed several of the key uncertainties ”